Stay updated on Daratumumab for AML/High-Risk MDS Clinical Trial
Sign up to get notified when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.

Latest updates to the Daratumumab for AML/High-Risk MDS Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page’s displayed revision/version has been bumped from v3.5.2 to v3.5.3, indicating a website/app release rather than an update to the clinical trial information.SummaryDifference0.1%

- Check25 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision: v3.5.0 added; Revision: v3.4.3 removed.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page. No changes to study data or page navigation are indicated.SummaryDifference0.1%

- Check89 days agoChange DetectedAdded Revision: v3.4.2. Removed the notice about lapse in government funding and the previous Revision: v3.4.1 entry.SummaryDifference0.5%

- Check97 days agoChange DetectedAdded a government funding lapse notice and a page revision indicator (v3.4.1). Removed the previous revision indicator (v3.4.0).SummaryDifference0.5%

Stay in the know with updates to Daratumumab for AML/High-Risk MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.